Related Experiment Video
Updated: May 19, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience
Eugene Braunwald1, Marc S Sabatine
1TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ebraunwald@partners.org
The Journal of Thoracic and Cardiovascular Surgery
|August 21, 2012
Summary
The Thrombolysis in Myocardial Infarction (TIMI) study group pioneered research in cardiovascular disorders. TIMI has conducted 50 trials on treatments including thrombolytic agents, impacting global cardiovascular medicine.
Area of Science:
- Cardiovascular Research
- Clinical Trials
- Translational Medicine
Background:
- Established in 1984, the Thrombolysis in Myocardial Infarction (TIMI) study group initially compared thrombolytic agents for heart attack treatment.
- Supported by the National Heart, Lung, and Blood Institute, TIMI has evolved into a global research network.
Observation:
- TIMI has successfully completed 50 multicenter clinical trials across 45 countries.
- The network collaborates with over 1000 sites, demonstrating extensive international reach.
- Research has expanded beyond thrombolytics to include antithrombotics, antiplatelets, and anti-inflammatories.
Findings:
- TIMI has developed widely adopted risk assessment scores.
- Established robust biomarker and pharmacogenetics programs.
- Investigated a broad spectrum of cardiovascular drug classes.
Implications:
- TIMI's research significantly contributes to reducing cardiovascular morbidity and mortality.
- Ongoing trials focus on novel agents for diverse cardiovascular conditions.
- The group's extensive data and risk scores inform clinical practice globally.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...